Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of the β-Lactamase Inhibitor Vaborbactam (RPX7009) in Healthy Adult Subjects

• Published in: Antimicrobial agents and chemotherapy Vol. 60; no. 10; pp. 6326 - 6332
• Main Authors: Griffith, David C., Loutit, Jeffery S., Morgan, Elizabeth E., Durso, Stephanie, Dudley, Michael N.
• Format: Journal Article
• Language: English
• Published: United States American Society for Microbiology 01.10.2016
• Subjects: Administration, Intravenous; Adult; Boronic Acids; Boronic Acids - administration & dosage; Boronic Acids - adverse effects; Boronic Acids - pharmacokinetics; Enterobacteriaceae; Female; Half-Life; Healthy Volunteers; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 1-Ring - administration & dosage; Heterocyclic Compounds, 1-Ring - adverse effects; Heterocyclic Compounds, 1-Ring - pharmacokinetics; Humans; Male; Pharmacology

Vaborbactam (formerly RPX7009) is a member of a new class of β-lactamase inhibitor with pharmacokinetic properties similar to those of many β-lactams, including carbapenems. The pharmacokinetics and safety of vaborbactam were evaluated in 80 healthy adult subjects in a first-in-human randomized, pla...